{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:15:34Z","timestamp":1791270934790,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005228.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T00:00:00Z","timestamp":1396224000000}}],"reference-count":106,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005228.pub4","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T11:29:32Z","timestamp":1396265372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Interventions for preventing neuropathy caused by cisplatin and related compounds"],"prefix":"10.1002","volume":"2014","author":[{"given":"James W","family":"Albers","sequence":"first","affiliation":[{"name":"University of Michigan; Department of Neurology; 1C325\/0032 University Hospital 1500 E. Medical Center Drive, Box 0316 Ann Arbor USA MI 48109-0032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Johns Hopkins Outpatient Center; Neurology; 601 North Caroline Street Baltimore Maryland USA MD 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano-Bicocca; Dipartimento di Chirurgia e Medicina Interdisciplinare; Via Cadore 48 Monza Italy 20900"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross C","family":"Donehower","sequence":"additional","affiliation":[{"name":"Johns Hopkins University; Division of Medical Oncology; Baltimore USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,31]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD005228.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00520-006-0072-3","article-title":"A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results","volume":"14","author":"Argyriou","year":"2006","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1002\/14651858.CD005228.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/WNL.0b013e31822e045c","article-title":"Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer","volume":"77","author":"Arrieta","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1525-1438.1996.06050415.x","article-title":"Neurotoxicity of cisplatin +\/- reduced glutathione in the first-line treatment of advanced ovarian cancer","volume":"6","author":"Bogliun","year":"1996","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.1995.13.1.26","article-title":"Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial","volume":"13","author":"Cascinu","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD005228.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1743-7563.2010.01344.x","article-title":"Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy","volume":"6","author":"Chay","year":"2010","journal-title":"Asia Pacific Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1525-1438.1995.05020081.x","article-title":"Weekly cisplatin +\/- glutathione in relapsed ovarian carcinoma","volume":"5","author":"Colombo","year":"1995","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/- amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"Vos","year":"2005","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1525-1438.1999.99029.x","article-title":"Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix","volume":"9","author":"Gallardo","year":"1999","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.1995.13.2.490","article-title":"Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities","volume":"13","author":"Gandara","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00833914","article-title":"The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo","volume":"239","author":"Hovestadt","year":"1992","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10147-009-0015-3","article-title":"Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study","volume":"15","author":"Ishibashi","year":"2010","journal-title":"International Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1385\/MO:20:3:237","article-title":"Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study","volume":"20","author":"Kanat","year":"2003","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD005228.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 8","key":"10.1002\/14651858.CD005228.pub4-BIB0017|cit17","first-page":"83","article-title":"Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma","volume":"23","author":"Rose","year":"1996","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejca.2010.10.006","article-title":"The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients","volume":"47","author":"Knijn","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD005228.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00520-010-1018-3","article-title":"The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial","volume":"19","author":"Kottschade","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00520-006-0018-9","article-title":"N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data","volume":"14","author":"Lin","year":"2006","journal-title":"Supportive Care in Cancer"},{"issue":"7","key":"10.1002\/14651858.CD005228.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","article-title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","volume":"14","author":"Lorusso","year":"2003","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0022|cit22","first-page":"1117","article-title":"Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors","volume":"27","author":"Lu","year":"2008","journal-title":"Ai Zheng [Chinese Journal of Cancer]"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/CAD.0b013e32832a2dc1","article-title":"Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity","volume":"20","author":"Milla","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2003.05.139","article-title":"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy","volume":"21","author":"Pace","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1008353505916","article-title":"Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group","volume":"10","author":"Planting","year":"1999","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/gyno.1997.4832","article-title":"A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer","volume":"67","author":"Roberts","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"14","key":"10.1002\/14651858.CD005228.pub4-BIB0027|cit27","first-page":"617","article-title":"Glutathione in the prevention of cisplatin induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer","volume":"112","author":"Schmidinger","year":"2000","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1008211226339","article-title":"Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial","volume":"8","author":"Smyth","year":"1997","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199001113220204","article-title":"Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer","volume":"322","author":"Gerritsen van der Hoop","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD005228.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00900961","article-title":"The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial","volume":"241","author":"Gerven","year":"1994","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1742-7843.2009.00512.x","article-title":"Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature","volume":"106","author":"Ali","year":"2009","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/etm.2012.678","article-title":"Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: a meta-analysis","volume":"4","author":"Ao","year":"2012","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/01.WNL.0000148609.35718.7D","article-title":"Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial","volume":"64","author":"Argyriou","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1534735405282842","article-title":"Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care","volume":"4","author":"Block","year":"2005","journal-title":"Integrative Cancer Therapies"},{"issue":"8","key":"10.1002\/14651858.CD005228.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF02334967","article-title":"Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione","volume":"13","author":"Bogliun","year":"1992","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0036|cit36","unstructured":"Program in Evidence-based Care Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer Toronto (ON): Cancer Care Ontario; 2012 May 15 [Archived 2011 Sep]. Program in Evidence-based Care Evidence-based Series No.: 12-6 ARCHIVED 2011. https:\/\/www.cancercare.on.ca\/toolbox\/qualityguidelines\/clin-program\/systemic-ebs\/"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005228.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/0959-8049(95)00144-8","article-title":"Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences","volume":"31A","author":"Capizzi","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002800050723","article-title":"Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin","volume":"41","author":"Cassidy","year":"1998","journal-title":"Cancer Chemotherapy & Pharmacology"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/S0959-8049(99)81943-1","article-title":"An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients [abstract no: 1529]","volume":"35","author":"Catalano","year":"1999","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopha.2012.01.002","article-title":"The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study","volume":"66","author":"Chen","year":"2012","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00003495-200161050-00012","article-title":"Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome","volume":"61","author":"Culy","year":"2001","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005228.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00023210-200721001-00006","article-title":"Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review","volume":"21","author":"Grandis","year":"2007","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/- amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"Vos","year":"2005","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001813-200307000-00006","article-title":"Protection against oxaliplatin acute neurosensory toxicity by venlafaxine","volume":"14","author":"Durand","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"12 Pt 1","key":"10.1002\/14651858.CD005228.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1002\/14651858.CD005228.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2007.15.3767","article-title":"Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy (letter)","volume":"26","author":"Gamelin","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdg051","article-title":"Amelioration of docetaxel\/cisplatin induced polyneuropathy by alpha-lipoic acid (letter)","volume":"14","author":"Gedlicka","year":"2003","journal-title":"Annals of Oncology"},{"issue":"1-3","key":"10.1002\/14651858.CD005228.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0960-0760(92)90205-W","article-title":"ACTH\/MSH like peptides in the treatment of cisplatin neuropathy","volume":"43","author":"Gispen","year":"1992","journal-title":"Journal of Steroid Biochemistry & Molecular Biology"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.1987.5.4.574","article-title":"WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma","volume":"5","author":"Glover","year":"1987","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0360-3016(89)90283-6","article-title":"Clinical trials of WR-2721 and cis-platinum","volume":"16","author":"Glover","year":"1989","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008390-200312000-00012","article-title":"Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1686)","volume":"13","author":"Glover","year":"2003","journal-title":"Melanoma Research"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/1097-0142(20011115)92:10<2517::AID-CNCR1602>3.0.CO;2-Z","article-title":"A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188)","volume":"92","author":"Gradishar","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005228.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3816\/CCC.2005.s.006","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"Grothey","year":"2005","journal-title":"Clinical Colorectal Cancer"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00001813-200304000-00010","article-title":"Phase I study of amifostine as a cytoprotector of the gemcitabine\/cisplatin combination in patients with advanced solid malignancies","volume":"14","author":"Haigentz","year":"2003","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s001200050332","article-title":"Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer. [German]","volume":"38","author":"Heidenreich","year":"1999","journal-title":"Urologe"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005228.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0959-8049(94)00497-S","article-title":"Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration","volume":"31A","author":"Hilkens","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00520-005-0782-y","article-title":"Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin\/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group","volume":"13","author":"Hilpert","year":"2005","journal-title":"Supportive Care in Cancer"},{"issue":"25","key":"10.1002\/14651858.CD005228.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1200\/JCO.2007.13.5251","article-title":"Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity","volume":"25","author":"Hochster","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0060|cit60","first-page":"1","article-title":"Neuroprotective effect of vitamin E supplementation (commentary)","volume":"64","author":"Kesari","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD005228.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2003.11.005","article-title":"Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer","volume":"21","author":"Leong","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01262569","article-title":"Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin","volume":"5","author":"Lissoni","year":"1997","journal-title":"Supportive Care in Cancer"},{"issue":"12","key":"10.1002\/14651858.CD005228.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0959-8049(99)00159-8","article-title":"Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status","volume":"35","author":"Lissoni","year":"1999","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0064|cit64","first-page":"93","article-title":"A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha","volume":"16","author":"Lissoni","year":"2002","journal-title":"In Vivo"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JTO.0b013e318186fb0d","article-title":"Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)","volume":"3","author":"Miller","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD005228.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/1097-0142(19880601)61:11<2192::AID-CNCR2820611110>3.0.CO;2-A","article-title":"Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721","volume":"61","author":"Mollman","year":"1988","journal-title":"Cancer"},{"issue":"22","key":"10.1002\/14651858.CD005228.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2003.02.086","article-title":"Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group","volume":"21","author":"Moore","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.65.3.501","article-title":"Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial","volume":"65","author":"Pace","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD005228.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial","volume":"74","author":"Pace","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1023\/A:1011184609963","article-title":"Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy","volume":"12","author":"Penz","year":"2001","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD005228.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1023\/A:1011628900089","article-title":"Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor","volume":"12","author":"Rick","year":"2001","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","article-title":"Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients","volume":"12","author":"Wang","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mds211","article-title":"Ca\/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis","volume":"24","author":"Wen","year":"2013","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.soncn.2007.05.001","article-title":"Peripheral neuropathy related to chemotherapy","volume":"23","author":"Wilkes","year":"2007","journal-title":"Seminars in Oncology Nursing"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0075|cit75","first-page":"208","article-title":"[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity]","volume":"32","author":"Dong","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0076|cit76","first-page":"2059","article-title":"Efficacy of reduced glutathione in preventing and reducing neurotoxicity of oxaliplatin [Chinese]","volume":"17","author":"Pang","year":"2010","journal-title":"Chinese Journal of Cancer Prevention and Treatment"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1853-0028(11)70034-9","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. [Spanish]","volume":"3","author":"Romano","year":"2011","journal-title":"Neurologia Argentina"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Carozzi VA Canta A Oggioni N Sala B Chiorazzi A Meregalli C Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies Experimental Neurology 2010 301 9","DOI":"10.1016\/j.expneurol.2010.09.004"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00227662","article-title":"Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats","volume":"84","author":"Cavaletti","year":"1992","journal-title":"Acta Neuropathologica"},{"issue":"6","key":"10.1002\/14651858.CD005228.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14740338.3.6.535","article-title":"Chemotherapy-induced peripheral neurotoxicity","volume":"3","author":"Cavaletti","year":"2004","journal-title":"Expert Opinion on Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Annals of Oncology"},{"issue":"2-3","key":"10.1002\/14651858.CD005228.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0022-510X(89)90187-1","article-title":"Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity","volume":"93","author":"Elderson","year":"1989","journal-title":"Journal of the Neurological Sciences"},{"issue":"1 Suppl 3","key":"10.1002\/14651858.CD005228.pub4-BIB0084|cit84","first-page":"49","article-title":"Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity","volume":"18","author":"Gandara","year":"1991","journal-title":"Seminars in Oncology"},{"issue":"4 Suppl 15","key":"10.1002\/14651858.CD005228.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: Neurotoxicity","volume":"30","author":"Grothey","year":"2003","journal-title":"Seminars in Oncology"},{"issue":"10","key":"10.1002\/14651858.CD005228.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1517\/14656566.5.10.2159","article-title":"A review of oxaliplatin and its clinical use in colorectal cancer","volume":"5","author":"Grothey","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green SE (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0088|cit88","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"Pt 5","key":"10.1002\/14651858.CD005228.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/116.5.1017","article-title":"Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function","volume":"116","author":"Krarup-Hansen","year":"1993","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD005228.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003495-199957030-00003","article-title":"Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy","volume":"57","author":"Links","year":"1999","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM199001113220210","article-title":"Cisplatin neurotoxicity","volume":"322","author":"Mollman","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mus.1109","article-title":"Thalidomide neuropathy in patients treated for metastatic prostate cancer","volume":"24","author":"Molloy","year":"2001","journal-title":"Muscle & Nerve"},{"issue":"15","key":"10.1002\/14651858.CD005228.pub4-BIB0093|cit93","first-page":"5756","article-title":"Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine","volume":"9","author":"Pisano","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","article-title":"Cisplatin (cis-diamminedichloroplatinum II)","volume":"6","author":"Prestayko","year":"1979","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.34.7.934","article-title":"Peripheral sensory neuropathy and cisplatin chemotherapy","volume":"34","author":"Roelofs","year":"1984","journal-title":"Neurology (Minneap)"},{"issue":"4 Suppl 8","key":"10.1002\/14651858.CD005228.pub4-BIB0096|cit96","first-page":"83","article-title":"Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma","volume":"23","author":"Rose","year":"1996","journal-title":"Seminars in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0014-4886(95)90054-3","article-title":"Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db\/db) mice","volume":"132","author":"Schmidt","year":"1995","journal-title":"Experimental Neurology"},{"issue":"7","key":"10.1002\/14651858.CD005228.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9","article-title":"Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies","volume":"54","author":"Thompson","year":"1984","journal-title":"Cancer"},{"issue":"3-4","key":"10.1002\/14651858.CD005228.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00688308","article-title":"The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry","volume":"69","author":"Tomiwa","year":"1986","journal-title":"Acta Neuropathologica"},{"issue":"9-10","key":"10.1002\/14651858.CD005228.pub4-BIB0100|cit100","first-page":"1527","article-title":"Toxic effects of cis-dichlorodiammineplatinum(II) in man","volume":"63","author":"Hoff","year":"1979","journal-title":"Cancer Treatment Report"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0101|cit101","first-page":"1116","article-title":"Cisplatin neuropathy: clinical and nerve conduction correlation (abstr)","volume":"17","author":"Wald","year":"1994","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD005228.pub4-BIB0102|cit102","first-page":"A170","article-title":"Cisplatin neuropathy not prevented by ACTH(4-9) analog (abstr)","volume":"45 (Suppl 4)","author":"Wald","year":"1995","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD005228.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.44.3_Part_1.488","article-title":"The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro","volume":"44","author":"Windebank","year":"1994","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005228.pub4-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005228.pub4-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005228.pub2","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005228.pub4-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005228.pub3","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005228.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T03:02:31Z","timestamp":1708743751000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005228.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,31]]},"references-count":106,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005228.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,31]]}}}